Big Pharma Sharma's Bullets: Imbruvica’s Decline, IRA Crosshairs, and What it Could Mean for AbbVie
I’m testing out a new series called “Quick Take”, where I react to interesting data, graphics, charts, etc. and extrapolate potential implications. This series is intended to be short, thought-provoking, and easily digestible.
For today’s edition, I’ll be examining the latest prescription and sales trends for the BTK inhibitor space and what it means for Imbruvica (ibrutinib) and AbbVie. Imbruvica was particularly top of mind after CMS released its first ten drugs set for Medicare price negotiations (press release). Imbruvica is accompanied by several other best-sellers, seen in the snapshot below.
📣 Announcements
📉Special Discount: Before we get into the meat of this post, I wanted to let you know that I’m issuing a special offer to anyone who is interested in becoming a paid subscriber to Big Pharma Sharma. For a limited time, I’m offering 25% off, forever, for both monthly and yearly plans. This means you’ll be getting unfettered access to BPS for $36 per month if you’re a monthly subscriber or $30 per month if you’re a yearly subscriber. Lock-in the best rate [HERE] so you don’t miss out on any future updates of mine
🎯Sponsored Posts: If you are looking to raise awareness of your product, company, or platform to a dedicated audience of hundreds of BioPharma budget decision-makers, I encourage you to reach out to me about sponsoring future posts. You’ll get premium space at the top of future posts to advertise your product, platform, or brand and custom links. I’m also open to other formats and structures. Here are some examples other substackers have used to great success (link). If you’d like to discuss pricing and implementation for sponsored posts, please feel free to reach out to me via email, substack, linkedin, Twitter/X, or Threads.
Now let’s get into today’s Quick Take…